C eliac disease is a multisystem autoimmune disorder triggered by exposure to dietary gluten in genetically predisposed individuals. A systematic review of 38 studies published from 1992 to 2004 found celiac disease prevalence estimates in North America and Western Europe that ranged from 0.15% to 1.87%, based on studies with intestinal biopsy confirmation of positive serologic test results; estimates in studies of US adults ranged from 0.40% to 0.95%. 1 More recently, a study of 7798 persons 6 years or older who participated in the 2009-2010 National Health and Nutrition Examination Survey found a celiac disease prevalence of 0.71%, based on positive serologic test results or a reported celiac disease diagnosis and being on a gluten-free diet. 2 Celiac disease can be diagnosed at any age and presents more frequently in adults than in children. [3] [4] [5] [6] The clinical presentation and natural history of celiac disease vary. Treatment is removal of dietary gluten. Classic celiac disease presents with symptoms of malabsorption and various nongastrointestinal signs and symptoms. Celiac disease may also be silent (the patient meets celiac disease diagnostic criteria but does not manifest common symptoms or signs) or subclinical (symptoms are below the celiac disease testing threshold). For silent or subclinical celiac disease, screening might enable initiation of treatment before overt symptoms develop, alleviate mild but unrecognized symptoms, prevent malabsorption and associated nutritional deficiencies, or prevent other adverse health consequences, such as gastrointestinal malignancy. 7-9 Evidence on the natural history of silent celiac disease is limited, although 3 US studies found that 0% to 15% of patients with positive serologic test results for celiac disease (without histologic confirmation) developed symptoms after 10 to 45 years.
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The purpose of this report was to systematically review the evidence on benefits and harms of celiac disease screening. The report was commissioned by the US Preventive Services Task Force (USPSTF) to inform a recommendation statement on celiac disease screening in persons 3 years or older. The USPSTF has not previously addressed celiac disease screening.
Methods

Scope of Review
Detailed methods are available in the full evidence report available at https://www.uspreventiveservicestaskforce.org/Page/Document /UpdateSummaryDraft/celiac-disease-screening?ds=1&s=celiac %20disease. 13 The focus of the review was on the effectiveness of screening for celiac disease in asymptomatic adults, adolescents, and children on morbidity, mortality, and quality of life. The analytic framework and key questions (KQs) to guide the review are shown in Figure 1 . The full report includes additional contextual questions (not reviewed systematically) on the prevalence and natural history of subclinical or silent celiac disease.
Data Sources and Searches
The Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Ovid MEDLINE databases were searched from 1991, 2005, and 1946, respectively, to June 14, 2016, for relevant studies and systematic reviews. The search strategies are listed in the eMethods in the Supplement. Reference lists of relevant articles were also reviewed.
Study Selection
Two reviewers independently evaluated each study to determine inclusion eligibility. Studies were selected on the basis of inclusion and exclusion criteria developed for each KQ. For screening and diagnosis, the population of interest was asymptomatic adults, adolescents, or children 3 years or older without known celiac disease who had not sought evaluation for possible celiac disease. The population included persons at higher risk because of family history or presence of conditions associated with celiac disease, such as type 1 diabetes mellitus, autoimmune thyroiditis, or Down syndrome, as well as persons not known to be at higher risk. For treatment, the population of interest was asymptomatic persons with screen-detected celiac disease. Studies of mildly symptomatic patients were also included if no studies were available in asymptomatic populations. Screening tests were serologic tests or questionnaires. Included were randomized trials, cohort studies, and case-control studies performed in primary care or primary care-applicable settings of screening vs no screening, targeted vs universal screening, treatment vs no treatment, and immediate vs delayed treatment that reported morbidity (including clinical outcomes related to nutritional deficiencies and gastrointestinal symptoms), cancer incidence, mood and anxiety, child growth outcomes, infection rates, quality of life, mortality, or harms associated with screening or treatment. For diagnostic accuracy, cohort and cross-sectional studies that compared screening tests against intestinal biopsy as the reference standard were included. The Marsh classification system categorizes biopsy findings based on the presence of intraepithelial lymphocytosis (Marsh 1 or greater), crypt hyperplasia (Marsh 2 or greater), and villous atrophy (Marsh 3 or greater). 15 The presence of villous atrophy (Marsh 3 or 4) is considered the hallmark of celiac disease, with Marsh 1 and 2 more equivocal. Studies reporting only intermediate outcomes such as laboratory values for nutritional or other deficiencies and studies that evaluated diagnostic accuracy using a case-control design were excluded. To summarize the diagnostic accuracy of screening tests in populations not restricted to asymptomatic persons, good-quality systematic reviews published since 2015 were also included. The selection of literature is summarized in the literature flow diagram ( Figure 2 ).
Data Extraction and Quality Assessment
One investigator extracted details about each article's study design, patient population, setting, screening method, treatment regimen, analysis, follow-up, and results. A second investigator reviewed data abstraction for accuracy. Two investigators independently applied criteria developed by the USPSTF 16 to rate the quality of each study as good, fair, or poor. The quality assessment criteria are reported in the eMethods in the Supplement. Discrepancies were resolved through consensus.
Data Synthesis and Analysis
The aggregate internal validity (quality) of the body of evidence for each KQ (good, fair, poor) was assessed using methods developed by the USPSTF, based on the number, quality, and size of studies; consistency of results between studies; and directness of evidence. 16 There were too few studies to perform meta-analysis.
Sample sizes ranged from 62 to more than 12 000 participants. Three studies in the review focused on diagnostic accuracy of testing in children, adolescents, or both 18-20 ; 6 evaluated a mixed population of children and adults [21] [22] [23] [24] [25] [26] ; and the remainder focused on testing in Overall, including studies of persons with symptoms or in whom symptom status was not described, the systematic review found high strength of evidence that tissue transglutaminase (tTG) immunoglobulin A (IgA) was associated with high accuracy for diagnosis of celiac disease (sensitivity and specificity both 
Key questions
What is the effectiveness of screening vs not screening for celiac disease in asymptomatic adults, adolescents, or children on morbidity, mortality, or quality of life? Results were not reported for the subgroup of patients with Marsh 3 biopsy findings. Sensitivity was 70% and specificity 81% for patients screened because they had a first-degree relative (n = 32), and sensitivity was 64% and specificity 93% for patients with type 1 diabetes mellitus (n = 40).
Treatment of Screen-Detected Celiac Disease
Key Question 5. Does treatment of screen-detected celiac disease lead to improved morbidity, mortality, or quality of life compared with no treatment?
One fair-quality trial (n = 40) evaluated a gluten-free vs normal gluten-containing diet in asymptomatic adults (median age, 42 years) diagnosed with celiac disease through screening of relatives of persons with celiac disease ( Table 3 , panels A and B; eTable 3 in the Supplement).
41 Diagnosis of celiac disease was based on a positive serum EMA test result. Although biopsy was performed, histopathological findings of celiac disease were not required for study entry, and researchers were blinded to biopsy results until completion of the trial. At baseline, the mean ratio of villous height to crypt depth was 1.0 in the gluten-free diet group and 0.8 in the non-gluten-free diet group, indicating presence of villous atrophy; 2 patients in each group had a normal ratio of villous height to crypt depth (>2.0). At 1 year, participants on a gluten-free diet reported significant improvements in total gastrointestinal symptoms vs a non-glutenfree diet based on the overall Gastrointestinal Symptoms Ratings Scale (difference in mean change, −0. There were no differences between groups in intermediate outcomes such as mean blood hemoglobin level, mean serum total iron level, mean body mass index, mean percent total body fat, or mean lumbar spine or femoral neck bone mineral density. After 2 years, more than 90% of participants reported adherence to the gluten-free diet, and greater improvements in histopathological findings were observed in the gluten-free diet group at 1 year compared with the non-gluten-free diet group.
A recent randomized trial that screened persons with a first-or second-degree relative with celiac disease and randomized patients to immediate notification and initiation of a gluten-free diet vs no notification or initiation of a gluten-free diet was terminated, with no results available. 42 Three small, observational Abbreviations: BMD, bone mineral density; BMI, body mass index; EMA, endomysial antibodies; GFD, gluten-free diet; GSRS, Gastrointestinal Symptoms Rating Scale; PGWB, Psychological General Well-Being; SF-36, 36-Item Short Form Health Survey; VAS, visual analog scale.
1 systematic review (56 diagnostic accuracy studies and 12 other systematic reviews) n = 62 to >12 000
One good-quality systematic review found tTG antibody tests associated with high sensitivity and specificity in populations not restricted to asymptomatic persons. Based on new studies, the pooled sensitivity (%) in the systematic review was 92. One small, fair-quality trial of screen-detected, asymptomatic adults found a gluten-free diet associated with small improvements in gastrointestinal symptoms (less than 1 point on a 1-7 scale) vs no gluten-free diet after 1 y, but there were no changes on most quality-of-life outcomes. Evidence was imprecise; consistency could not be determined (1 study). The trial included for key question 5 reported no withdrawals "as a result of major symptoms or complications." No other study on harms of gluten-free vs non-gluten-free diet in persons with screen-detected celiac disease was identified. Evidence was imprecise; consistency could not be determined (1 study). Table 4 summarizes the evidence reviewed for this update. No studies of screening vs no screening or targeted vs universal screening for celiac disease in adults, adolescents, or children aged 3 years or older were identified. Although serologic tests for celiac disease used in screening appear to be highly accurate and study designs were appropriate, almost all studies on diagnostic accuracy evaluated populations with symptoms of celiac disease or in whom symptom status was not reported. Two studies that specifically evaluated asymptomatic patients at high risk for celiac disease based on family history or presence of conditions associated with celiac disease reported lower sensitivity and inconsistent specificity. 19, 22 Neither of these studies were conducted in the United States. Only 1 Finland-based randomized trial evaluated the effectiveness of gluten-free diet vs no gluten-free diet in asymptomatic adults with screen-detected celiac disease. 41 That trial found initiation of a gluten-free diet in screen-detected, asymptomatic adults associated with improved gastrointestinal symptoms, although effects were relatively small (<1 point on a scale of 1-7). There were no effects on most measures of quality of life; no harms resulting in withdrawal from the diet occurred. In this study, patients had a first-degree relative with celiac disease and were diagnosed on the basis of serologic testing. Histologic findings of celiac disease were not required for entry. Although most patients had some degree of villous atrophy at baseline, it is possible that this trial could have underestimated benefits of treatment in patients with histologically proven celiac disease. No study evaluated the effects of immediate initiation of a gluten-free diet vs initiation delayed until the development of symptoms in asymptomatic persons diagnosed with celiac disease. A recent randomized trial of immediate notification and initiation of a gluten-free diet for screen-detected celiac disease vs no notification or gluten-free diet was terminated; we were unable to determine reasons for study termination. 42 Three small, observational studies on effects of a gluten-free diet for asymptomatic celiac disease that did not meet inclusion criteria because they lacked a glutencontaining diet comparison group found no clear associations with quality of life.
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The major limitation of this review is the lack of evidence to address the KQs. In addition, although numerous studies evaluated the diagnostic accuracy of tests for celiac disease in patients who were not asymptomatic, the applicability of findings to screening settings is uncertain. Meta-analysis was not possible, and publication bias could not be formally assessed. Inclusion was restricted to English-language articles, but no non-English-language articles were found on benefits or harms of screening or treatment that appeared to meet inclusion criteria. Although during the review of abstracts some non-English-language articles were identified that assessed diagnostic accuracy, none were clearly conducted in asymptomatic populations.
An emerging issue is the treatment of celiac disease based on serologic testing, without histologic confirmation. The number of patients who are diagnosed with celiac disease or initiate a glutenfree diet based on serologic testing alone is unknown but may be increasing in clinical practice, despite guideline recommendations to obtain histologic confirmation prior to initiation of treatment.
A related issue is how to classify persons with positive serologic findings but negative or nondiagnostic findings on biopsy and manage their care. The likelihood that such patients will go on to develop overt celiac disease requires further investigation and has important implications for understanding effects of treatment. Although there continues to be research on pharmacological treatments for celiac disease, 46-49 such treatments are considered an adjunct to a gluten-free diet, which remains the mainstay of therapy. Additional research is needed to address all of the KQs addressed in this report. For screening, trials of screening vs no screening that evaluate clinical outcomes are needed. Trials that target high-risk populations (based on family history or presence of conditions associated with celiac disease) would likely provide a higher yield of screen-detected persons than trials that screen persons at lower or average risk, resulting in greater statistical power to detect effects, and might be more informative for an initial screening study. Additional studies are needed to determine the accuracy of serologic testing in asymptomatic persons. Trials are also needed on the effects of initiation of a gluten-free diet vs no gluten-free diet in screen-detected individuals and on the effects of immediate initiation at diagnosis vs initiation delayed until the development of symptoms. The in-progress Celiac Disease and Diabetes-Dietary Intervention and Evaluation Trial (CD-DIET) (ClinicalTrials.gov Identifier: NCT01566110), which involves screening of children and adults with type 1 diabetes mellitus for asymptomatic celiac disease followed by randomization to a gluten-free or no gluten-free diet, is designed to assess outcomes (including diabetes control, bone mineral density, and health-related quality of life) over 1 year and should help clarify effects of screening in higher-risk individuals. 50 Ideally, future studies would provide information on long-term outcomes related to nutritional deficiencies such as osteoporotic fractures, cancer, and mortality. Because of the uncertain natural history of positive serologic findings without histologic changes, trials should focus on patients with histologic findings of celiac disease or report analyses stratified according to baseline histologic findings. Trials should evaluate populations across the age spectrum, including children, adolescents, and adults, because celiac disease can be diagnosed in any of these age groups. Additional research is also needed to better understand the natural history of subclinical and silent celiac disease, including the proportion of patients who develop symptoms, the proportion who develop complications, and the proportion in whom serologic findings, histologic findings, or both resolve without treatment. Some data suggest that subclinical or silent celiac disease is associated with a lower risk of developing complications than symptomatic celiac disease.
Conclusions
Although some evidence was found regarding diagnostic accuracy of tests for celiac disease, little or no evidence was identified to inform most of the key questions related to benefits and harms of screening for celiac disease in asymptomatic individuals. More research is needed to understand the effectiveness of screening and treatment for celiac disease, accuracy of screening tests in asymptomatic persons, and optimal screening strategies. 
Systematic Reviews
Criteria:
• Comprehensiveness of sources considered/search strategy used.
• Standard appraisal of included studies.
• Validity of conclusions.
• Recency and relevance are especially important for systematic reviews.
Definition of ratings from above criteria: Good: Recent, relevant review with comprehensive sources and search strategies; explicit and relevant selection criteria; standard appraisal of included studies; and valid conclusions. Fair: Recent, relevant review that is not clearly biased but lacks comprehensive sources and search strategies. Poor: Outdated, irrelevant, or biased review without systematic search for studies, explicit selection criteria, or standard appraisal of studies.
Case-Control Studies
• Accurate ascertainment of cases • Nonbiased selection of cases/controls with exclusion criteria applied equally to both.
• Response rate.
• Diagnostic testing procedures applied equally to each group.
• Measurement of exposure accurate and applied equally to each group.
• Appropriate attention to potential confounding variables.
Definition of ratings based on criteria above: Good: Appropriate ascertainment of cases and nonbiased selection of case and control participants; exclusion criteria applied equally to cases and controls; response rate equal to or greater than 80 percent; diagnostic procedures and measurements accurate and applied equally to cases and controls; and appropriate attention to confounding variables. Fair: Recent, relevant, without major apparent selection or diagnostic work-up bias but with response rate less than 80 percent or attention to some but not all important confounding variables. Poor: Major selection or diagnostic work-up biases, response rates less than 50 percent, or inattention to confounding variables.
Randomized Controlled Trials and Cohort Studies
• Initial assembly of comparable groups:
o For RCTs: adequate randomization, including first concealment and whether potential confounders were distributed equally among groups. o For cohort studies: consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts.
• Maintenance of comparable groups (includes attrition, cross-overs, adherence, contamination).
• Important differential loss to follow-up or overall high loss to followup.
• Measurements: equal, reliable, and valid (includes masking of outcome assessment).
